Skip to main content
. 2022 Feb 26;10(3):366. doi: 10.3390/vaccines10030366

Figure 2.

Figure 2

Participants’ post-vaccination information. (A) Interval between receiving a COVID-19 vaccine and participating in this study (n = 10,064). (B) Time of COVID-19 vaccine breakthrough infection (n = 471). (C) Characterization of participants who experienced COVID-19 vaccine breakthrough infections based on the type of vaccine and number of doses (n = 471; 4.7%). * The perception was calculated out of the total number of participants who experienced vaccine breakthrough infection (n = 471); ** the perception was calculated out of the total number of participants who received the vaccine (Table 3).